(HealthDay News) — Venous thromboembolism (VTE) risk varies across hormonal contraceptives, according to a research letter published online Feb. 10 in the Journal of the American Medical Association.

which studied datasets and uncovered indications that specifically type I protein S deficiency is linked to venous thromboembolism. “That was a nice, exciting way of being able to look at how we ...

The study revealed the risk of developing venous thromboembolisms from various types of synthetic hormones, providing ...

Denmark: A recent study published in the Journal of the American Medical Association (JAMA) has shed light on the varying ...

(MENAFN- EIN Presswire) Leading companies such as LEO Pharma, Sanofi, Daiichi Sankyo Inc, are driving advancements in Venous Thromboembolism treatments to enhance patient care. LAS VEGAS , NV ...

TAT and several other markers demonstrated an ability to predict the development of venous thromboembolism in patients with cervical cancer.